НТФФ Полисан - фармацевтическое производство

Intelligent
protection of health

REMAXOL

solution for infusion. Metabolic agent

Reduces cytolysis, which is expresses as reduction of amplifiers, aspartate aminotransferase, alanine aminotransferase.

REMAXOL® solution for infusion

REMAXOL

Remaxol is a balanced infusional solution with the hepatoprotective activity.

Brand name:REMAXOL®

Dosage form:solution for infusion.

Therapeutic category:metabolic agent.

REMAXOL® is balanced solution for infusion with hepatoprotective effect. Transition of anaerobic processes to the aerobic, improving of energy supply of hepatocytes, increasing of macroergs synthesis, increasing of resistance of hepatocyte membranes to lipid peroxidation, restoration of activity of antioxidant enzymes are intensified under the effect of the drug product. REMAXOL® reduces cytolysis, which is expresses as reduction of amplifiers, aspartate aminotransferase, alanine aminotransferase.

REMAXOL® promotes reduction of bilirubin and its fractions, improves the excretion of conjugated bilirubin in the bile. Reduces the activity of hepatocyte excretory enzymes - alkaline phosphatase and gamma-glutamyl transpeptidase, promotes the oxidation of cholesterol to bile acids.

Inquiry of instruction

Your name, surname, first name*
Сountry *
Сity *
E-mail *
Your Message Subject *
Your subject *

Submitting the message shall mean the consent for processing and storing the personal data of the patient and/or the applicant by POLYSAN or its qualified person. The sender shall confirm that the provided information is complete, accurate and authentic.

Reporting of data shall keep within the current law without prejudice to the rights and interests of the third parties.

The information shall be held in strict confidence. Applicant data shall not be publicly disclosed but may be submitted to the Federal Service for Supervision in Health Care, unless otherwise specified when submitting the report.

A representative of POLYSAN pharmacovigilance department may contact the applicant to ascertain the information submitted in the report.

POLYSAN shall cease processing of personal data having received a claim via e-mail sent to safety@polysan.ru or via the feedback service at the company’s website www.polysan.ru.

Пожалуйста подтвердите что вы человек, введя буквы с изображения.
This is a captcha-picture. It is used to prevent mass-access by robots. (see: www.captcha.net)

THE CHOICE OF MEDICATION AND DRUG USE SUPERVISION CAN BE EXERCISED ONLY BY A DOCTOR WHO WILL ALWAYS CONSIDER PATIENT’S PERSONAL FACTORS.

Up